Open access
Open access
Powered by Google Translator Translator

#ESMO19 – Randomized Trial: Improved Overall Survival with a CDK4/6 Inhibitor for Hormone Receptor-positive, ERBB2-negative Advanced Breast Cancer

30 Sep, 2019 | 00:40h | UTC

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2: A Randomized Clinical Trial – JAMA Oncology (free)

Commentary: Two Studies Show CDK4/6 Inhibitors Improve Overall Survival in Advanced Breast Cancer [ESMO 2019 Press Release] (free)

#ESMO19 – Just presented at the European Society of Medical Oncology Congress 2019 in Barcelona